The estimated Net Worth of Vikram Karnani is at least $21.2 Milione dollars as of 22 February 2021. Mr. Karnani owns over 8,358 units of Horizon Therapeutics Plc stock worth over $12,114,390 and over the last 8 years he sold HZNP stock worth over $5,029,659. In addition, he makes $4,063,290 as Executive Vice President e President - International at Horizon Therapeutics Plc.
Sign up
Mr. Karnani HZNP stock SEC Form 4 insiders trading
Vikram has made over 9 trades of the Horizon Therapeutics Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 8,358 units of HZNP stock worth $728,734 on 22 February 2021.
The largest trade he's ever made was exercising 47,337 units of Horizon Therapeutics Plc stock on 4 January 2021 worth over $5,505,293. On average, Vikram trades about 11,194 units every 30 days since 2017. As of 22 February 2021 he still owns at least 104,165 units of Horizon Therapeutics Plc stock.
You can see the complete history of Mr. Karnani stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vikram Karnani biography
Vikram Karnani serves as Executive Vice President, President - International of the Company. Prior to that, he served as our senior vice president, rheumatology business unit from February 2017 to March 2018, and before that, from July 2014 until February 2017, he served as our general manager, specialty business unit. Prior to joining Horizon, Mr. Karnani was with Fresenius Kabi, a global health care company, where he served as vice president of the therapeutics and cell therapy business, from October 2011 to July 2014. Mr. Karnani also held various positions in business development, corporate strategy and strategic marketing within Fenwal Inc., a global blood technology company that was acquired by Fresenius Kabi, from November 2008 to October 2011. Mr. Karnani brings nearly 17 years of cross-functional expertise across a multitude of industries, including medical devices, management consulting, semiconductors and cellular telecommunications.
What is the salary of Vikram Karnani?
As the Executive Vice President e President - International of Horizon Therapeutics Plc, the total compensation of Vikram Karnani at Horizon Therapeutics Plc is $4,063,290. There are 4 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of $13,873,200.
How old is Vikram Karnani?
Vikram Karnani is 45, he's been the Executive Vice President e President - International of Horizon Therapeutics Plc since 2020. There are 21 older and 2 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
What's Vikram Karnani's mailing address?
Vikram's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC,, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN, L2, 4.
Insiders trading at Horizon Therapeutics Plc
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... e Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
What does Horizon Therapeutics Plc do?
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
What does Horizon Therapeutics Plc's logo look like?
Complete history of Mr. Karnani stock trades at Horizon Therapeutics Plc
Horizon Therapeutics Plc executives and stock owners
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Timothy Walbert,
Chairman of the Board, President, Chief Executive Officer -
Timothy P. Walbert,
Chairman, Pres & CEO -
Barry Moze,
Executive Vice President, Chief Administrative Officer -
Paul Hoelscher,
Chief Financial Officer, Executive Vice President -
Vikram Karnani,
Executive Vice President, President - International -
Paul W. Hoelscher,
Exec. VP & CFO -
Andy Pasternak,
Exec. VP & Chief Strategy Officer -
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
Exec. VP & Chief Medical Officer -
Michael Grey,
Lead Independent Director -
Jeffrey Himawan,
Independent Director -
H. Thomas Watkins,
Independent Director -
James Shannon,
Independent Director -
William Daniel,
Independent Director -
Pascale Witz,
Independent Director -
Susan Mahony,
Independent Director -
Irina Konstantinovsky,
Chief Human Resource Officer, Executive Vice President -
Daniel Camardo,
Executive Vice President, President - U.S. -
Jeffrey Kent,
Senior Vice President, Head of Medical Affairs and Outcomes Research -
Andy Pasternak,
Executive Vice President, Chief Business Officer -
Geoffrey Curtis,
Executive Vice President - Corporate Affairs, Chief Communications Officer -
Tina Ventura,
Senior Vice President, Investor Relations -
Michael DesJardin,
Executive Vice President - Technical Operations and Corporate Quality -
Brian Beeler,
Executive Vice President, General Counsel -
Aaron L. Cox,
Exec. VP of Fin. & CFO -
Jane Gonnerman,
Group VP of Corp. Devel., Chief of Staff & Office of the CEO -
Geoffrey M. Curtis,
Exec. VP of Corp. Affairs & Chief Communications Officer -
Sean M. Clayton J.D.,
Exec. VP & Gen. Counsel -
Timothy Ayers,
Chief Compliance Officer & VP -
Dr. Karin Rosen M.D., Ph.D.,
Exec. VP of R&D and Chief Scientific Officer -
Miles W. McHugh,
Chief Accounting Officer & Sr. VP -
Robert Carey,
EVP & Chief Business Officer -
Jeff Himawan,
Director -
Gino Santini,
Director -
Timothy J. Ackerman,
SVP, Commercial Operations -
Miles W Mc Hugh,
Sr VP & Princ. Acctg Officer -
George P Hampton,
See remarks -
Virinder Nohria,
Director -
Ronald Pauli,
Director -
Vaere Robert J De,
EVP & CFO -
Therapeutics Holdings Llc V...,
10% owner -
Todd N Smith,
SVP, Marketing & Alliance Mgmt -
David Happel,
EVP, Commercial Dev & Strategy -
Eric Mosbrooker,
SVP, Orphan Business Unit -
Shao Lee Lin,
EVP, Head of R&D and CSO -
Jeff Kent,
See remarks -
Jeffrey W Bird,
Director -
Michael Adatto,
Senior VP Sales & Managed Care -
Bio Ventures Ii Lp Quaker,
10% owner -
Venture Fund Vi Lp Atlas Ve...,
-
Peter Johann,
Director -
Jean Francois Formela,
Director -
Venture Fund Vi Lp Atlas Ve...,
-
Woodlands Health Ventures F...,
10% owner -
Louis C Bock,
Director -
Hubert Birner,
Director -
John B Thomas,
EVP, Corporate Strategy and IR -
David George Kelly,
EVP, Company Secretary -
John J Kody,
EVP, Chief Commercial Officer -
Balaji Venkataraman,
-
Aaron Cox,
EVP, Chief Financial Officer -
Jeffrey W Sherman,
EVP and Chief Medical Officer -
Karin Rosen,
EVP, R&D & CSO -
Elizabeth H.Z. Thompson,
EVP, Research & Development -
Sean M. Clayton,
EVP, General Counsel -
Jacopo Leonardi,
Pres., Global Commercial Ops -
Patrick Mc Ilvenny,
Chief Accounting Officer